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Abstract
Sézary syndrome (SS) is a rare and aggressive variant of Cutaneous T-Cell Lymphoma characterized by neoplastic
distribution mainly involving blood, skin, and lymph-node. Although a role of the skin microenvironment in SS
pathogenesis has long been hypothesized, its function in vivo is poorly characterized. To deepen this aspect, here we
compared skin to blood-derived SS cells concurrently obtained from SS patients highlighting a greater proliferation-index
and a PI3K/AKT/mTORC1 pathway activation level, particularly of mTOR protein, in skin-derived-SS cells. We proved that
SDF-1 and CCL21 chemokines, both overexpressed in SS tissues, induce mTORC1 signaling activation, cell proliferation
and Ki67 up-regulation in a SS-derived cell line and primary-SS cells. In a cohort of 43 SS cases, we observed recurrent
copy number variations (CNV) of members belonging to this cascade, namely: loss of LKB1 (48%), PTEN (39%) and
PDCD4 (35%) and gains of P70S6K (30%). These alterations represent druggable targets unraveling new therapeutic
treatments as metformin here evaluated in vitro. Moreover, CNV of PTEN, PDCD4, and P70S6K, evaluated individually or
in combination, are associated with reduced survival of SS patients. These data shed light on effects in vivo of skin-SS cells
interaction underlying the prognostic and therapeutic relevance of mTORC1 pathway in SS.
Introduction
Sézary syndrome (SS) is a rare aggressive leukemic variant of
cutaneous T-cell lymphomas (CTCLs) in which malignant
T cells accumulate in the skin, lymph nodes and blood,
typically resulting in a shortened life expectancy with a
median of survival of 63 months [1, 2].
SS cells express CD45R0+ CCR7+CD27+ CD62L+
accordingly with a central memory (CM) T cells phenotype
representing mature long-lived lymphocytes with a high
proliferative and migratory potential [3]. SS cells carry
recurrent chromosomal alterations as loss of 17p, 10q, 19p
and gains of 17q, 8/8q [4–6] and deep sequencing studies
have identified mutations in genes involved in epigenetic,
DNA repair, cell cycle, apoptotic and TCR-signaling
mechanisms [7–12]. Despite these findings, no specific
therapy is available yet to treat SS [13].
SS cells grow poorly in vitro also in presence of multiple
cytokines, growth factors, macrophages, dendritic and mast
cells indicating that nutrients and signals released by tumor
microenvironment are essential to support their proliferation
and survival [14–18]. We previously demonstrated that the
PTEN, that antagonizes the PI3K/AKT signaling [19], is
commonly downregulated in SS [20] and that AKT is
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mainly activated in skin tumor cells with respect to blood
[20]. These data underline how different environments, as
skin and blood, may affect SS cells in response to stimu-
latory or co-stimulatory signals [20].
Here, we compared skin to blood-derived SS cells con-
currently obtained from SS patients to investigate the effect
of the microenvironment on SS cells in vivo. This approach
allowed us to identify the PI3K/AKT/mTORC1 activation
in skin-resident SS cells, a pathway already found altered in
CTCL by others [21, 22], that we also analyzed at the
genomic and biochemical level in SS cell lines and primary
tumor cells.
Materials and methods
Patients and CTCL cell lines
This study was conducted in accordance with the Declara-
tion of Helsinki and approved by theEthical Committee of
the Istituto Dermopatico dell’Immacolata (ID n. 4/CE/
2015). Diagnosis of SS was based on described criteria [1].
Matched SS cell derived from blood and skin were con-
currently obtained from SS patients and analyzed in paral-
lel. SS cell isolation from blood was performed as
previously described [5]. For samples with a TCR-Vβ+
clonality ≥ 90%, CD4+ neoplastic cells were not purified,
otherwise we selected them using the CD4+ untouched
separation protocol (Miltenyi Biotech, Germany). In all
experiments performed in this study, the primary tumor
cells were indicated as SS cells. Isolation of SS cells from
fresh skin punches of SS patients was performed by over-
night incubation at 37 °C in RPMI 1640 supplemented with
10% fetal bovine serum (FBS) (Sigma-Aldrich St. Louis,
MO, USA) and 1 mg/ml Collagenase type IV (Worthington,
Lakewood, NJ). Skin-resident SS cells were isolated from
fresh-frozen OCT-embedded skin biopsies using a laser
micro-dissector (PALM Microlaser System, Bernried, Ger-
many). All biopsies were selected from the files of IDI
Pathology and specimens were classified according to the
EORTC classification [1].
Clinical characteristics of SS patients used in matched
analyses, in vitro signaling, cell proliferation assay and
chemotaxis are shown in Supplementary Table S1 and S2.
Hut78 (TIB161), H9 (HTB 176) and HH (CRL2105) cell
lines established from peripheral blood of CTCL patients
were obtained from American Type Culture Collection
(ATCC).
Immunohistochemistry (IHC)
IHC analyses for CD4 (1:20; Monosan,Uden, The Nether-
lands) and Ki67 (1:100, Dakocytomation, Glostrup, Den-
mark), were performed as described; [23] detection of
phosphorylated (p) P70S6K(Thr389)(1:20.000, Abcam,
Cambridge, UK) was done using Immpress HRP-Polymer
detection kit (Vector Laboratories, Burlingame, CA) on
cytospins of primary SS and H9 cells suspension fixed with
4% of Paraformaldehyde (Sigma-Aldrich) and paired par-
affin- skin-biopsies. Double staining was performed as
described in Supplementary Information
Results
Skin-derived SS cells show a higher proliferation-
index than matched circulating SS cells
We analyzed by IHC the expression of the proliferation
marker Ki67 on 17 SS skin biopsies. The percentage of
Fig. 1 Skin-derived SS cells show a higher proliferation-index (PI)
compared to matched circulating SS cells, a data that correlates with
tumor burden. a Fresh blood and skin-derived cells concurrently
obtained from patient SS82 were analyzed by FACS and the percen-
tage of Ki67+ SS cells (i.e., PI) was calculated within the neoplastic
clone identified by CD3, CD4 and CCR7 positivity and co-expression
of TCR-Vβ2 chain rearrangement; b In SS68 patient, PI was measured
by FACS within the TCR-Vβ 6.7 clone and in matched OCT skin
biopsy by double IHC where KI67+ SS cells were recognized by a co-
staining with specific anti-TCR-Vβ6.7 (black) and anti- Ki67 (purple)
antibodies; in the insert, IHC for Ki67 performed on matched paraffin-
skin biopsy in which neoplastic cells were recognized for morphologic
features by hematoxylin counter-staining. In IHC experiments, Ki67+
SS cells were calculated by a pathologist, counting at least 400 tumor
cells in high-power fields with a 40x object lens; c A positive corre-
lation between matched skin-PI values and tumor burden expressed as
expansion of circulating clonal TCR-Vβ+ cells was also observed
(n= 17, R= 0.73, P= 0.001 for Spearman test)
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Ki67+ neoplastic cells (the Proliferation Index, PI) varied
from 5 to 50% (mean 16.23 ± 13.38). We also measured the
PI by FACS on 11 blood-derived SS samples and it ranged
from 0.64 to 5% (mean 1.63% ± 1.29). (Table S1). These
results indicated that the PI values were clearly different
between skin and blood (P < 0.001). However, since this
counting was evaluated on SS cells deriving from two
different compartments by two different techniques, we
compared the PI of matched skin and blood samples con-
currently obtained from eight SS patients. In these cases, the
percentage of Ki67+ SS cells was calculated, using a gat-
ing strategy, within the neoplastic clone recognized by the
co-expression of CD3, CD4, CCR7 and the specific rear-
rangement of TCR-Vβ chain by FACS (three samples) as
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showed in Figure S1 and by double IHC (five samples) (two
representative cases are shown in Fig. 1a, b). In these
matched cases we confirmed that skin-derived SS cells
exhibited a higher PI respect to blood-derived SS cells
(n= 8, 11 ± 15% versus 1.9 ± 1.4%; fold change (FC)=
5.8; P= 0.01). To note that PI values obtained by IHC for
Ki67 were comparable with those obtained by dual IHC
(see 8th and 9th columns of the Table S1). We then cor-
related the PI values of the 17 SS paraffin-skin biopsies with
matched clinical data available as CD4/CD8 ratio, eosino-
phil count, percentage of circulating clonal TCR-Vβ+ cells
and survival. Results obtained revealed a significant direct
relationship between PI of skin-derived SS cells and the
tumor burden expressed as percentage of circulating clonal
Vβ+ cells concurrently measured in these individuals (n=
17, R= 0.73, P= 0.001) (Fig. 1c and Table S1).
Skin-derived SS cells show a higher level of mTOR
activation than matched circulating SS cells
Next, we analyzed in detail the pathway of PI3K/AKT/
mTOR that regulates proliferation and survival in matched
skin and blood SS cells. For this purpose, the protein of
blood and skin purified SS cells of SS68 and SS81 indivi-
duals were used in a pairwise-comparison of phospho levels
of 16 members belonging to PI3K/AKT/mTOR pathway
[24] using a kinase array (Fig. 2a). The results, expressed as
FC values calculated using the matched circulating SS cells
as reference, indicated an enhanced activation of many
components of this cascade in skin-derived cells. Higher
skin FC values (from 1.61 to 3.38) were observed in both
patients for PRAS40(Thr246), an inhibitory subunit of
mTORC1, mTOR(Ser2481), that phosphorylated in this
position may represent both mTORC1/2 complexes [25, 26]
BAD(Ser112) that, in this status, abrogates its pro-apoptotic
activity and PDK1(Ser241) which is a 3-phosphoinositide
dependent kinase traditionally linked to AKT activation
[24] (Fig. 2a).
We found, only in patient SS81, a hyper-phosphorylation
of the multifunctional kinase GSK3A(Ser21) (FC= 3.73),
of p70S6K(Thr421/Ser424) which is a direct downstream
member of mTORC1 (FC= 1.81) and of ERK1/2, a central
component of RAS/MAP kinase signaling involved in
motility and proliferation (FC= 2.23). With the exceptions
of GSK3B(Ser9) showing higher activation in circulating
cells with a FC of 0.28 in SS68, all other members of the
cascade displayed comparable phosphorylation levels
between blood and skin-derived SS cells (Fig. 2a).
Among the more skin-activated members, we validated
mTOR and PDK1 on four patients (Table S1). Results
obtained confirmed a higher phospho levels in skin of
mTOR(Ser2481), with FC values ranging from 3.9 to
22.9, and PDK1(Ser241) with FC ranging from 1.6 to 5.6 in
all samples (Fig. 2b left and right panel). Validation of
pERK confirmed its skin hyper activation in all three
patients analyzed with FC values ranging from 1.2 to 12.8
(Fig. S3). Additionally, we evaluated the activation of
mTORC1 signaling by IHC detection of its downstream
member, pP70S6K(Thr389), on additional three paired
skin-blood samples (Table S1) and H9 cells used as positive
control (Fig. S4). Compared to above kinase data, pP70S6K
(Thr 389) appeared more expressed in skin respect to
matched blood SS cells in all three cases studied possibly
reflecting a clinical heterogeneity and/or different ther-
apeutic treatments among patients analyzed and/or the dif-
ferent techniques used to perform these experiments. One
out of three cases analyzed is showed in Fig. 2c.
SDF-1 and CCL21 chemokines activate mTORC1
pathway, promote tumor proliferation and up-
regulate the Ki67 expression in H9 cell line and
primary SS cells
mTOR is a central environmental sensor that integrates
survival/proliferation and metabolism signals. It represents
the catalytic subunit of TORC1 and TORC2, two distinct
complexes linked by a negative feedback loop, able to
regulate different functions and downstream targets [27].
The above described results indicated that both complexes
are activated in skin-derived SS cells; however, the finding
that TORC1 pathway is triggered in cancer cells by SDF-1
and CCL21 [28–30], two chemokines highly expressed in
SS tissues and able to chemoactract SS cells in vitro [23, 37]
prompted us to investigate in detail this mechanism. To
mimic skin conditions, we stimulated the H9 cells and
primary SS cells with SDF-1 and CCL21 to analyze the
activation level of mTORC1 downstream members. A sig-
nificant increase of the level of phosphorylation of P70S6K
Fig. 2 Comparison of phosphorylation levels of members of PI3K/
AKT pathway between matched circulating and skin-resident SS cells.
a upper panel, a phospho-proteins kinase array was probed with pro-
tein lysates of blood and skin-derived SS cells concurrently obtained
from 2 SS patients. The dots corresponding to p-mTOR, p-PRAS40, p-
BAD and p-PDK1 were indicated with black lines. Housekeeping
protein is represented by *. a lower panel, graph represents the den-
sitometric values of dots corresponding to each protein normalized to
housekeeping and expressed as fold change (FC) with respect to
matched blood SS cells. b left panel, WB validation for indicated
proteins was accomplished in matched skin (S) and blood (B) SS cells
of four SS patients. Because of the timing of patient recruitment, the
gels were run at separate times and the lanes were composed for the
figure. b right panel, graph represents the densitometric values of
normalized phosphorylated proteins expressed as FC with respect to
matched blood SS cells. c IHC for pP70S6K shows a weak positivity
in 4% of circulating SS cells and an intense positivity in about 70% of
skin-resident SS cells concurrently obtained from patient SS 82. Inserts
show SS cells at higher magnification. A weak positivity is also
observed in neutrophil cells (arrow)
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(pP70S6K) and S6RP (pS6RP) was observed after 30 min
of H9 stimulation with both chemokines compared to
untreated cells. Both phosphorylations were significantly
inhibited by a 2 h pretreatments with rapamycin, the specific
inhibitor of mTORC1 [31] (Fig. 3a). As P70S6K can
directly phosphorylate PDCD4 promoting its degradation
and releasing the inhibitory effect on the initial step of
protein translation [32], we next evaluated the phosphory-
lated and non-phosphorylated form of this protein in H9
cells exposed to SDF-1 for different times. After 30 min we
observed an increase of pPDCD4 level that was inhibited by
2 hours (h) of rapamycin pretreatment whereas an increase
Fig. 3 SDF-1 and CCL21 chemokines activate mTORC1 pathway,
promote tumor proliferation and up-regulate the Ki67 expression in H9
cell line and primary SS cells. a left panel, serum-starved H9 cells
were left untreated (UNT) or pre-incubated with rapamycin for 2 h and
then stimulated or not with SDF-1 or CCL21 for 30 min at indicated
concentrations. WB was performed for the specified proteins. a Right
panel, densitometric data normalized to β-actin were expressed
as mean ± SEM of three independent experiments. Graph shows
phospho protein levels expressed as FC respect to UNT samples *P ≤
0.02, **P= 0.05; °°P ≤ 0.0001; b upper panel, SS cells from patients
cultured in complete medium at high density, left UNT or pre-
incubated with 30 nM of rapamycin for 2 h and then stimulated or not
for 30 min with 100 ng/ml of SDF-1 or b lower panel,with 10 ng/ml of
CCL21. WB was performed for the specified proteins. Because of the
timing of patient recruitment, the gels were run at separate times and
the lanes were composed for the figure. c upper panel, SS cells were
cultured in vitro at high density for 5 days in complete medium used
alone (NT) or supplemented with 300 ng/ml of SDF-1 or CCL21 in
presence or absence of rapamycin used at 30 nM or IL2 at 30U/ml plus
IL7 at 10 ng/ml. Cell proliferation was determined by MTT assay and
data are expressed as means of OD values ± SEM. Statistics were
calculated as paired t-test. *P= 0.05; **P= 0.01; c lower panel, cell-
activation induced by 300 ng/ml of SDF-1 was evaluated in SS cells
obtained from SS94 patient, by Ki67 detection using FACS within
neoplastic clone recognized by CD3,CD4, CCR7 and TCR-Vβ1 chain
rearrangement
Blood and skin-derived Sezary cells: differences in proliferation-index, activation of PI3K/AKT/mTORC1. . .
of PDCD4 level, able to block protein synthesis [32], was
observed after a longer rapamycin exposure peaking after
24 h (Fig. S5). Then, to verify that mTORC1 activation
occurs also in primary malignant lymphocytes we analyzed
freshly circulating SS cells from five patients (Table S2).
Also in this system we observed an increase of pS6RP level
in response of 100 ng/ml of SDF-1 and 10 ng/ml of CCL21
that was inhibited by rapamycin (Fig. 3b). Lastly, we
wondered if these chemokines also promoted SS cells
proliferation. Purified SS cells from 5 patients (Table S2),
cultured at high density in complete medium with or
without SDF-1 or CCL21, demonstrated that both chemo-
kines significantly enhanced proliferation, although to lesser
extent than T-cell growth factors like IL2/IL7; we assessed
that rapamycin inhibited this chemokine-induced effect
(upper panel, Fig. 3c). In two cases (Table S2), we also
evaluated the cell-activation status induced by SDF-1
demonstrating that it up-regulated the Ki67 expression
while rapamycin inhibited it (one representative case is
shown in lower panel of Fig. 3c). Even if with less efficacy,
CCL21 showed similar results (Fig. S6).
SS patients show frequent genome copy number
variations (CNVs) of members of the PI3K/AKT/
mTORC1 pathway
Since we previously demonstrated that PTEN is deleted in
36% of SS individuals but no mutation was detected within
its coding region [20], we wondered if and how often
additional genetic mechanisms potentially leading to PI3K/
AKT/mTOR pathway dysregulation occurred in SS. With
this aim we investigated the CN status of the main members
Fig. 4 Frequency of CN changes of members belonging to PI3K/AKT/
mTOR pathway observed in a cohort of 43 SS patients. a CN data
were obtained using Affymetrix 10 K and SNP6.0 platforms. Mono-
allelelic gains and losses are represented in red and blue, respectively.
Bi-allelic loss is indicated as*. Genes not covered by 10 K array are
represented in gray. Percentages reflect the lesion frequency observed
for each gene. b CN values for PDCD4, LKB1 and P70S6K genes
obtained by ddPCR versus 10 K/SNP6.0 arrays on a total of
30 samples plus diploid reference gDNA (Affymetrix) used as con-
trols. Graph is based on a linear regression model. Solid line indicates
the fitting curve. Dotted line represents 95% confidence limits. P= <
0.0001. c CN values for LKB1, PTEN, PDCD4 and P70S6K obtained
by ddPCR on patients analyzed for kinase array validation (°) and
mTORC1 in vitro signaling (*). Losses are represented in blue, gains
in red
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of this cascade using the Affymetrix arrays data of circu-
lating tumor cells derived from 63 SS samples (43 patients
plus 20 F-UP) and 3 CTCL cell lines [20]. We observed that
many components of PI3K/AKT/mTOR pathway showed
frequent deletions and amplifications that, with few excep-
tions observed for PTEN, appeared as monoallelic defects
(Fig. 4a). We detected recurrent deletions involving TS
genes representing upstream negative regulators of mTOR
signaling: we found loss of LKB1 in 9 of 21 cases (48%) as
measured by the higher genome resolution SNP6.0 platform
and we confirmed PTEN deletion in 17 of 43 cases (39%) in
agreement with our previous study [20]. Among the
downstream members of mTORC1 pathway we found
recurrent deletions of the TS PDCD4 in 15 of 43 cases
(35%), gains of the proto-oncogene P70S6K in 13 of 43
(30%) and of RAPTOR in 10 of 43 cases (23%) and
deletions of P90S6K in 7 out 43 cases (16%) (Fig. 4a).
Moreover, we found CN variations (CNV) of two other
downstream effector members of mTORC1: loss of S6RP in
6 of 43 (14%) and the gain of EIF4EBP1 (alias 4EBP1) in 5
of 43 cases (12%). Other components of this pathway
including mTOR, PIK3CG, RHEB, TSC1, AMPKG1,
GSK3a, PI3KCA, PI3KCD, and PRAS40 showed a CNV at
lower frequencies ranging from 2.3 to 7%, whereas the
remaining pathway components did not show any CN
changes. CN abnormalities of multiple members of this
signaling co-occurred also in H9, Hut78 and HH cell lines
as shown in the left columns of Fig. 4a.
We validated CN values found for PDCD4, LKB1and
P70S6K in 10 patientsby ddPCR. We obtained values
ranging from 0.97 to 1.33 for CN loss (PDCD4 and LKB1),
from 2.72 to 2.95 for CN gain (P70S6K) and from 1.85 to
2.38 for WT conditions (Table S3). Thus, ddPCR values
were in agreement with those obtained with 10 K and
SNP6.0 arrays as demonstrated by Pearson’s correlation
(R= 0.94, P < 0.0001) and the linear regression (P=
0.0001) (Fig. 4b).
Based on these results, we demonstrated by ddPCR that
CN changes of PTEN, PDCD4, LKB1 and P70S6K occur
also in SS patients used for phospho-array validation
(Fig. 2c) and TORC1 activation signaling in vitro (Fig. 3b)
as showed in Fig. 4c. Moreover, we confirmed CN changes
of LKB1, PDCD4 and P70S6K by ddPCR also in the skin-
resident SS cells of three cases for whom we had genomic
DNA: SS30T2, SS60T1 and SS81T1. The same CN status
of these genes detected in circulating and skin-derived SS
cells of these patients (Table S3) indicated that these two
cellular subsets show a homogeneous genomic phenotype.
Multiple CNV of members of the PI3K/AKT/mTOR
pathway define survival classes in SS
Patients with CN loss of PTEN (n= 17), PDCD4 (n= 15)
and CN gain of P70S6K (n= 13) revealed an unfavorable
outcome compared to individuals with the corresponding WT
status of these loci showing a median of overall survival (OS)
of 48.4 months vs 73.1 months. (P= 0.04), 54 vs 74 months
(P= 0.015) and 48.4 vs 82 months (P= 0.002), respectively
(Fig. 5). No significant difference in survival was seen for
LKB1 deletions (data not shown) probably because of the
smaller sample size analyzed by SNP6 array (n= 23).
Kaplan Maier (KM) analysis revealed also a significant
Fig. 5 CN variations of PTEN,
PDCD4 and P70S6K correlate
with the outcome and define
survival classes in SS. SS
patients were identified by CNV
of PTEN (P= 0.04), PDCD4
(P= 0.015) and P70S6K (P=
0.0002) and analyzed by Kaplan
Meier (KM) analysis. KM
performed on four clusters of
patients identified from the total
number of lesions observed for
these genes (from 0 to 3)
showed a progressive shorter
survival with increasing number
of lesions (P= 0.002). Statistic
was calculated by Log-rank test
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difference in survival when patients were clustered in four
distinct groups associated to: (a) no lesions found for PTEN,
PDCD4 and P70S6K (n= 16); (b) a lesion affecting one
gene of three (n= 13); (c) lesions involving two genes of
three (n= 10); (d) lesions including all three genes (n= 4).
The resulting KM analyses demonstrated that SS patients
without lesions in three genes were long survivors, those
displaying one or two lesions showed a progressive shorter
outcome with a median OS of 73 and 59 months, respec-
tively, whereas patients with three lesions were associated
with the worst clinical outcome with a median OS of
25.7 months (P= 0.002) (Fig. 5).
Metformin inhibits mTORC1 signaling and migration
of SS cells induced by SDF-1
Genome alterations found here suggest that the losses of
TSs as PTEN, LKB1 and PDCD4 as well as the gain of the
oncogene P70S6K might converge toward an increased
oncogenic activity of PI3K/AKT/mTORC1 signaling and
that many members might represent novel therapeutic tar-
gets to treat SS (Fig. 6a) [33]. Among these, we focused on
TS LKB1, that represents the most altered gene with a loss
in 48% of cases studied. LKB1 is a kinase that activates
AMPK that, in turn, inhibits the mTOR signaling [34].
Drugs able to activate AMPK are therefore useful to fight
the hyperactive mTORC1 signaling and one of the most
commonly used is metformin, a repurposing antidiabetic
drug with direct antitumor properties [35]. Beyond gly-
cemic control, metformin inhibits mTORC1 signaling by
AMPK activation via LKB1 or by an AMPK-independent
mechanism, for example in a ragGTPase-dependent manner
[35, 36]. As the recurrent CN loss of LKB1 here described
might prejudice the LKB1/AMPK axis function in SS, we
wondered if metformin could have an effect on
mTORC1 signaling in this neoplasia. With this purpose, we
analyzed metformin pretreated H9 cells (n= 3) and primary
SS cells (n= 2) stimulated or not by SDF-1 that we found
more abundant in SS skin than CCL21, which is mainly
expressed in endothelial cells [37]. In both systems, 2 h-
exposure of metformin prevents mTORC1 activation as
demonstrated by the inhibition of S6RP phosphorylation by
a mechanism that appears to be AMPK-independent
(Figs. 6b, d and Fig. S7).
Metformin also inhibits chemotaxis of cancer cells
through mechanisms still not well understood [38]. As SS
cells express several chemokine receptors including
CXCR4 and CCR7 [23, 39] and they migrate in vitro in
response to SDF-1 and CCL21 [23, 37], we investigated the
effect of metformin on SS cells chemotaxis. Using a
Fig. 6 Diagram of skin interaction with Sezary cells and effects of
metformin in H9 cell line and primary SS cells. a Map of PI3K/AKT/
mTORC1 pathway including members CN changes found in 43 SS
individuals. Asterisks indicate therapeutic targets; b left panel, H9 cells
untreated (UNT) or pre-treated for 2 h with metformin at 10mM and
then stimulated or not for 30min with SDF-1 at 10 and 100 ng/ml were
analyzed by WB for indicated proteins as showed by one representative
experiment. b right panel, densitometric data normalized to β-actin were
expressed as mean ± SEM of 3 independent experiments. Graph shows
phospho protein levels expressed as FC respect to UNT samples *P= ≤
0.05. c H9 cells UNT or pre-treated for 2 h with metformin at 10mM or
1mM or rapamycin at 30 nM were allowed to migrate in response of
SDF-1 used at 300 ng/ml. d SS cells left UNT or 2 h-pretreated with
metformin and then stimulated with SDF-1 at 100 ng/ml were analyzed
by WB as above described as showed by one representative experiments;
e SS UNT or pre-treated for 2 h with 10mM or 1mM of metformin or
AMD3100 at 15 μM or rapamycin at 30 nM were allowed to migrate in
response to SDF-1 at 300 ng/ml. In both systems, migration results are
shown as an absolute number of CD4+ migrated cells measured by flow
cytometry. Each dot represents a sample; bars represent the mean of
migration counts. *P= 0.01, ° P= 0.0014; **and °° and ***; °°°P ≤
0.05 were calculated by paired t-test
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transwell assay we observed that metformin at 10 mM and
1 mM, significantly inhibited H9 cell migration towards
SDF-1 whereas a minor effect was observed with 30 nM
rapamycin pretreatment (Fig. 6c). Similarly, SS cells
obtained from patients (Table S2) were significantly
inhibited with pretreatments of metformin used at 10 mM
(n= 9) or 1 mM (n= 5) (Fig. 6e). A significant inhibition
was also observed with 15 μM of AMD3100, an antagonist
of CXCR4 that we used to verify the specificity of CXCR4-
SDF-1 binding(n= 4) whereas rapamycin at 30 nM inter-
fered less also with chemotaxis of SS cells (n= 4) (Fig. 6e).
This lower effect suggests that rapamycin, beyond mTOR
pathway [30, 40], interferes less with other signaling(s)
involved in locomotion respect to metformin. We also
proved that metformin inhibits chemotaxis toward CCL21
(Fig. S8).
Lastly, in agreement with the cytostatic effect of met-
formin, we observed a significant reduction of cell viability
in CTCL cell lines but not in low proliferating primary
circulating SS cells after metformin treatment, as demon-
strated by MTT and FACS analysis (Fig. S9).
Discussion
Previous studies have described SS cells as quiescent and
apoptotic-resistant malignant lymphocytes classifying SS
principally as an accumulative disorder [15, 41]. Although
earlier studies using tritiated thymidine labeling in vivo
generically indicated a higher SS cells proliferation in skin
and lymph nodes [42] here we demonstrated, with more
accuracy, to what extent the skin-resident SS cells pro-
liferate more respect to those of blood using the Ki67
analysis, a widely recognized marker of cell activation/
proliferation in daily pathologic practice [43]. We also
observed that skin PI increases with the expansion of tumor
burden measured as blood TCR-Vβ clonality indicating that
skin and blood compartments are interconnected, thus
supporting the concept that activation/proliferation plus
apoptosis resistance could determine the SS clinical
outcome.
Another key purpose of this study was to identify which
members of the PI3K/AKT/mTOR signaling are engaged
in vivo in SS. Using a skin-blood comparison approach, we
found that skin-derived SS cells mainly show a higher level
of mTORC1/mTORC2 activation than corresponding cir-
culating SS cells. In CTCL, the involvement of TORC1 is
already demonstrated by studies conducted on rapamycin, a
compound that mainly inhibits this complex [31], able to
reduce proliferation of CTCL cell lines, primary tumor cells
[21] and tumor size in xenograft mice [22]. Recent inves-
tigations demonstrated that SDF-1 and CCL21 chemokines
through their cognate receptors CXCR4 and CCR7, signals
to mTOR pathway in other cancers [28–30]. As SS cells
express several chemokine receptors [23, 37, 39] including
CXCR4 which is involved in metastatic processes and
CCR7 that is responsible for lymph-node homing [44], we
demonstrated that both SDF-1 and CCL21 activate
mTORC1 also in this malignancy. The importance of this
finding is supported by the ability of SS cells to migrate in
response to SDF-1 and CCL21/19 which are overexpressed
(SDF-1 over CCL21) in SS skin [37]. Since SS cells do not
express SDF-1 mRNA, but rather they seem to uptake the
SDF-1 released from epithelial, dendritic and endothelial
cells of the skin [23], we can speculate that SS cells move
toward skin through a chemotactic gradient [23]. This
hypothesis is further reinforced by the lack from SS cell
surface of CD26 peptidase able to cleave and inactivate
SDF-1 [23], by the versican overexpression, a proteoglycan
that enhances the SS locomotion toward SDF-1 [45] and by
the comparable levels of plasmatic SDF-1 found between
HDs and SS individuals (data not shown).
These results underline that, beyond migration, these
chemokines activate the TORC1signaling, pointing toward
processes as protein translation and cellular energy [46].
Moreover, similarly to what demonstrated on healthy CD4+
lymphocytes [47, 48] SDF-1 and CCL21 promote pro-
liferation and up-regulate Ki67 expression in SS cells
underlying the more activated phenotype of skin resident
respect to blood SS cells recently observed by Roelens et al.
[49]. Rapamycin inhibited both processes indicating that
both SDF-1 and CCL21 induce activation/proliferation by a
mTORC1-dependent mechanism(s) that have yet to be
clarified
Using SNP technology we also explore the PI3K/AKT/
mTOR pathway at the genomic level. We found multiple
CNV of members belonging to this cascade that map within
large genomic regions described as recurrently unbalanced
in SS as 10q and 17q chromosome (chr) [4–6]. Accordingly
with these findings, we observed concurrent CN losses of
PTEN and PDCD4, both localized at chr 10q23-25, in 30%
of the cases as well as concomitant CN gains of P70S6K
and RAPTOR, both mapping at chr 17q23-25 in 23% of the
samples analyzed. In addition, it is interestingly to note that
CNV of the pathway downstream members represented by
RPS6 and 4EBP1 genes, respectively involved in cap-
dependent translation and ribosome biogenesis [32, 46],
occurred in mutually exclusive manner; thus suggesting that
SS patients may cluster respect to these gene alterations
leading toward different routes of protein synthesis. CNVs
assume a very important role in SS since they appear more
common than TS/oncogene mutations with respect to other
cancers [50]. Accordingly with this feature, the SNPs [20]
and the latest NGS analyses [9, 11] revealed no or very few
mutations within PTEN coding region of SS individuals
while the CN loss of this gene, either in mono or biallelic
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defect, is a frequent event ranging from 20 to 36% of cases
[10, 12, 20]. Absence or very low frequency mutations
detected by NGS in LKB1, P70S6K and PDCD4 genes
in CTCL/SS lymphomas [10, 12] furthermore support
this hypothesis. The importance of CNV in SS is also
reinforced by the significant correlation between CN
changes and overall survival here demonstrated, indicating
these alterations as novel prognostic markers that poten-
tially reflect the alterations of the 10q23 and 17q23 loci on
which they map.
mTORC1 regulates protein synthesis and metabolism,
two interconnected routes which appear strongly compro-
mised in SS. In fact, in this study we found CNV of both
P70S6K and PDCD4 that might reflect a dysfunction of
mTORC1-dependent protein synthesis leading to an
increased cell size that might explain the larger SS cell
dimensions often observed [1, 51]. Moreover, we detected
recurrent loss of PTEN that under normal conditions
attenuates the upstream activation of mTORC1 through
PIP3 dephosphorylation [52] and loss of LKB1, that nor-
mally is able to activate AMPK, a kinase that inhibits
mTORC1 in low energy conditions [34, 53]. These genomic
defects might result in stoichiometric unbalance ultimate
leading to a constitutive TORC1 activation promoting a
metabolic shift: from oxidative phosphorylation, mainly
observed in quiescent/memory lymphocytes toward aerobic
glycolysis that increase the glucose demand (Warburg
effect) typically observed in activated lymphocytes [53].
Accordingly, rapamycin inhibits tumor growth decreasing
aerobic glycolysis in a mouse model of CTCL [54]. Con-
sidering the trafficking ability of SS cells [23, 37, 39] these
genomic dysfunctions promoting aerobic glycolysis and
protein translation might be functionally useful, in term of
energy, during the SS cells recruitment to skin and/or lymph
node by SDF-1 and CCL21, both able in turn, to promote
mTORC1 activation signaling and proliferation of these
cells. In summary, these results indicate that the genomic
changes here identified might be insufficient to induce SS
cell proliferation and emphasize the role of factors present
within the skin like cytokines [55], antigens able to engage
T-Cell Receptor [56] and the SDF-1 and CCL21 chemo-
kines here studied.
Members of this signaling with CN changes represent, for
SS, both novel (as LKB1, P70S6K) and already known (as
PI3K, mTOR) therapeutic targets [33]. Actually, the efficacy
of rapalogs and dual PI3K/mTOR inhibitors have been lar-
gely proven in vitro in T-cell lymphoma [57, 58] but, despite
these results, few clinical trials in CTCLs are ongoing
(http://www.tcllfoundation.org/current-clinical-trials. Detec-
tion of several genomic alterations in PI3K/AKT/mTORC1
pathway indicates that other specific compounds can be
tested as the metformin that we demonstrated to inhibit
in vitro mTORC1 activation and chemotactic ability of SS
cells. Recognition of these lesions might, moreover, improve
patient stratification for clinical trials enrollment of SS
patients.
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